





**Supplementary Figure S1. Effect of WU4 and WU8 on GvHD after allo-HCT.** Allo-HCT was performed as follows;  $5 \times 10^6$  TCD-BM (CD45.1+) and  $5 \times 10^5$  splenic T cells (CD45.2+) obtained from B6 mice were transplanted on day 0 into lethally irradiated (900 cGy on day -1) Balb/c allogeneic recipient mice. TCD-BM only group serves as no GvHD control. (A-B) Starting on day 3 after allo-HCT, we injected WU4, WU8, and BARI (4 mg/kg) subcutaneously once a day (5 days/week) for 3 weeks. The mice were monitored for survival and GvHD signs. (C) Whole splenocytes were analyzed for % of the recipient's APCs (CD11c+ and non-classical monocytes [NC Mo]) and (D) CD80-expressing BM-derived B cells (B220+) and neutrophils (NT) on day 6

after allo-HCT. LyG6-CD11b+Ly6C<sup>high</sup> and LyG6-CD11b+Ly6C<sup>middle</sup> serve as classical and intermediate monocyte subsets. \*p<.05, \*\* p<.01, and \*\*\* p<.001. All error bars are represented as mean±standard deviation.



**Supplementary Figure S2. Effect of WU6 on the expression of CXCR3 and T-bet in vitro.**

Primary T cells were isolated from B6 and treated with WU6 at indicated doses for 3 days in the presence of anti-CD3/CD28 activation beads. After 3 days, the expression of CXCR3 (A-B) and T-bet (C-D) in the CD4 and CD8 was determined by flow cytometry and the representative plots were represented in A-D.